Adverse Reaction To Diazepam; A Case Report

10.5580/2c92 ◽  
2012 ◽  
Vol 10 (1) ◽  
Keyword(s):  
Adverse Reaction ◽  
Case Report

Abstract #230: Bullous Pemphigoid-Adverse Reaction to Linagliptin (Tradjenta): A Case Report

2015 ◽  
Vol 21 ◽  
pp. 38-39
Author(s):  
Issac Sachmechi ◽  
Raya Galibov ◽  
Venkat Dirish Arukala
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Bullous Pemphigoid

Case report: Severe adverse reaction to oral Iohexol

1991 ◽  
Vol 44 (2) ◽  
pp. 137-138 ◽  
Author(s):  
J.R. Glover ◽  
B.M. Thomas
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Severe Adverse Reaction

scholarly journals Cutaneous adverse reaction during lithium treatment: a case report and updated systematic review with meta-analysis

2017 ◽  
Vol 5 (1) ◽  
Author(s):  
Martina Pinna ◽  
Mirko Manchia ◽  
Sergio Puddu ◽  
Giampaolo Minnai ◽  
Leonardo Tondo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Reaction ◽  
Case Report ◽  
Lithium Treatment ◽  
Meta Analysis ◽  
Cutaneous Adverse Reaction

Adverse reaction to mesalazine during therapy for Crohn's disease: A case report

2007 ◽  
Vol 39 (10) ◽  
pp. A74
Author(s):  
S. Piovan ◽  
A. Meneghel ◽  
A. Muraro ◽  
A. Capretta ◽  
F. Brotto ◽  
...  
Keyword(s):  
Adverse Reaction ◽  
Crohn’S Disease ◽  
Case Report ◽  
Crohn's Disease

scholarly journals Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report

2021 ◽  
Author(s):  
Stefano Consoli ◽  
Fedele Dono ◽  
Giacomo Evangelista ◽  
Maria D’Apolito ◽  
Daniela Travaglini ◽  
...  
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Status Migrainosus

scholarly journals Hydrochlorothizide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo

2019 ◽  
Vol 12 (2) ◽  
pp. bcr-2017-223528 ◽  
Author(s):  
Leo E Reap ◽  
Cassandra Rodd ◽  
Jose Larios ◽  
Michael Marshall
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Cutaneous Adverse Reaction ◽  
Common Causes ◽  
Erythematous Plaques ◽  
Exanthematous Pustulosis

Acute generalised exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction characterised by the appearance of erythematous plaques and papules with overlying non-follicular pinpoint pustules. Drugs are the cause of AGEP in approximately 90% of cases. The most common causes include anti-infective agents (aminopenicillins, quinolones, antibacterial sulfonamides and terbinafine), antimalarials and diltiazem. To the best of our knowledge, to date there has only been one report of hydrochlorothiazide-induced AGEP. There has never been a case report of losartan-induced AGEP. Here, we present a case of AGEP that is the second case purportedly caused by hydrochlorothiazide.

Adverse reaction after tetrathiomolybdate treatment for Wilson's disease: A case report

2006 ◽  
Vol 21 (11) ◽  
pp. 2030-2032 ◽  
Author(s):  
Valentina Medici ◽  
Carlo Pietro Trevisan ◽  
Maria Assunta Bigotto ◽  
Renata D'Incà ◽  
Diego Martines ◽  
...  
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Wilson’S Disease ◽  
Wilson's Disease

scholarly journals Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

2018 ◽  
Vol 11 (1) ◽  
pp. 119-124 ◽  
Author(s):  
Jorine de Haan ◽  
Johannes V. van Thienen ◽  
Michael Casaer ◽  
Rebekka A. Hannivoort ◽  
Kristel Van Calsteren ◽  
...  
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Pregnant Woman ◽  
Metastatic Melanoma ◽  
Targeted Therapies ◽  
Adverse Reactions ◽  
Tumour Progression ◽  
Single Case ◽  
Severe Adverse Reaction ◽  
Single Case Report

Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.

Sign in / Sign up

Export Citation Format

Share Document